“South Africa has successfully initiated 55,123 individuals on Lenacapavir, a long-acting HIV prevention injection administered twice yearly. The rollout, launched in June 2026, prioritizes vulnerable groups such as pregnant and breastfeeding mothers, offering a transformative solution to adherence challenges in HIV prevention.”
South Africa, a nation long at the epicenter of the global HIV epidemic, has reached a historic milestone in its public health journey. The Department of Health (DoH) announced that more than 55,000 individuals have been initiated on Lenacapavir, a groundbreaking twice-yearly injectable HIV prevention medication. This achievement, realized within just three months of the drug’s launch, signals a new era in HIV prevention strategies and demonstrates the country’s commitment to innovative healthcare solutions.
Background: HIV Burden in South Africa
South Africa continues to carry one of the highest HIV burdens globally, with millions living with the virus and thousands of new infections reported annually. Traditional prevention methods, such as daily oral pre-exposure prophylaxis (PrEP), have faced challenges with adherence. Many individuals struggle with daily pill regimens, leading to inconsistent protection. Lenacapavir, with its six-month dosing schedule, offers a practical solution, reducing the burden on patients and healthcare systems alike.
Launch of Lenacapavir
The initiative was officially launched in June 2026 by President Cyril Ramaphosa and Health Minister Dr. Aaron Motsoaledi. Within three months, the program expanded rapidly to 360 public health facilities across 24 districts in six provinces, underscoring the government’s determination to scale up access. The rollout was celebrated as a landmark achievement, positioning South Africa as a leader in adopting advanced HIV prevention technologies.
Demographics of Uptake
Data reveals that 71% of recipients are female, with a significant proportion being pregnant and breastfeeding mothers. This demographic focus reflects the government’s strategy to protect vulnerable populations and reduce mother-to-child transmission risks. Provincial uptake highlights Gauteng as the leader, with 26,357 initiations, followed by KwaZulu-Natal (11,941), North West (4,479), Western Cape (4,446), Mpumalanga (4,294), and Eastern Cape (3,606).
Safety and Regulation
The South African Health Products Regulatory Authority (SAHPRA) has approved Lenacapavir as safe and effective, following rigorous reviews of clinical and manufacturing data. Patients are advised to report any adverse events promptly, ensuring strong pharmacovigilance and clinical monitoring. This regulatory approval has bolstered public confidence in the drug’s safety profile.
Implementation Strategy
The rollout is part of a comprehensive PrEP-choice programme, ensuring individuals have access to multiple prevention options. Healthcare workers are closely monitoring uptake, commodity availability, service quality, and patient safety. The program’s design reflects lessons learned from previous HIV prevention initiatives, emphasizing flexibility, inclusivity, and patient-centered care.
Global and Regional Significance
South Africa’s adoption of Lenacapavir places it among the first African nations to integrate this drug into a national program. The initiative aligns with global efforts to expand access to long-acting HIV prevention tools, particularly in regions with high infection rates. By prioritizing vulnerable groups, South Africa sets a precedent for other countries grappling with similar challenges.
Challenges and Future Outlook
Despite the success, challenges remain. Ensuring equitable access across all provinces, addressing stigma, and maintaining consistent supply chains are critical to sustaining momentum. Phase two of the rollout, planned for 2027, aims to expand coverage to provinces not yet included, such as the Free State, Limpopo, and Northern Cape.
Conclusion
The rollout of Lenacapavir represents a transformative step in South Africa’s fight against HIV/AIDS. By initiating over 55,000 individuals within three months, the country has demonstrated the power of innovation, political will, and community engagement in tackling one of the world’s most persistent epidemics. As the program expands, Lenacapavir could redefine HIV prevention strategies, offering hope for a future where new infections are drastically reduced.
